A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib

NCT01377376 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

INDUSTRY

Sponsor class

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG: ARQ 197 and Erlotinib
DRUG: Placebo and Erlotinib

Sponsor

Kyowa Kirin Co., Ltd.